Steven M Horwitz MD

PubMed

• Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targets.
  Robert Stuver, Haiming Tang, Ahmet Dogan, Zachary D Epstein-Peterson, Shamir Geller
  Haematologica. 2026-03-19
• 1 citations
  CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.
  Joseph M Rocco, Joseph H Oved, Rikita J Patel, A Zara Herskovits, Namitha Nair
  Blood. 2026-02-26
• CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
  Silvia Escribano-Serrat, Ofrat Beyar-Katz, Roni Shouval, Parastoo B Dahi, Sigrun Einarsdottir
  American Journal of Hematology. 2026-01-30

Journal Articles

• Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study  
  Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
• TCR‐Δ Expression and Γδ+ T‐Cell Infiltrates in Primary Cutaneous Gamma‐Delta T‐Cell Lymphoma and Other Cutaneous T‐Cell Lymphoproliferative Disorders  
  Patricia Myskowski, Melissa Pulitzer, Steven Horwitz, Meenal Kheterpal, Shamir Geller, Allison Moskowitz, Histopathology

Abstracts/Posters

• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
  Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018